Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1992 May;55(5):359–361. doi: 10.1136/jnnp.55.5.359

Spasticity and white matter abnormalities in adult phenylketonuria.

P A McCombe 1, D B McLaughlin 1, J B Chalk 1, N N Brown 1, J J McGill 1, M P Pender 1
PMCID: PMC489075  PMID: 1602307

Abstract

A 19 year old male with phenylketonuria (PKU) developed a spastic paparesis 8 months after stopping his restricted phenylalanine diet. CT and MRI showed abnormalities of the deep cerebral white matter, and visual evoked response latencies were prolonged. The spasticity gradually improved over several months after resuming the PKU diet. A repeat MRI scan was unchanged. His brother also had PKU and ceased dietary restrictions, but his only neurological abnormality was a slight increase in the deep tendon reflexes of the lower limbs. CT and MRI of his brain was normal. DNA analysis showed that both brothers were homozygous for the same PKU mutation. These patients demonstrate that reversible neurological signs may develop in patients with classic PKU after ceasing dietary restrictions and that these may be associated with abnormalities seen on neuro-imaging.

Full text

PDF
359

Images in this article

360Image
on p.360

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Butler I. J., O'Flynn M. E., Seifert W. E., Jr, Howell R. R. Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia. J Pediatr. 1981 May;98(5):729–733. doi: 10.1016/s0022-3476(81)80832-3. [DOI] [PubMed] [Google Scholar]
  2. CROME L., TYMMS V., WOOLF L. I. A chemical investigation of the defects of myelination in phenylketonuria. J Neurol Neurosurg Psychiatry. 1962 May;25:143–148. doi: 10.1136/jnnp.25.2.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. DiLella A. G., Huang W. M., Woo S. L. Screening for phenylketonuria mutations by DNA amplification with the polymerase chain reaction. Lancet. 1988 Mar 5;1(8584):497–499. doi: 10.1016/s0140-6736(88)91295-0. [DOI] [PubMed] [Google Scholar]
  4. Giovannini M., Valsasina R., Villani R., Ducati A., Riva E., Landi A., Longhi R. Pattern reversal visual evoked potentials in phenylketonuria. J Inherit Metab Dis. 1988;11(4):416–421. doi: 10.1007/BF01800430. [DOI] [PubMed] [Google Scholar]
  5. Güttler F., Ledley F. D., Lidsky A. S., DiLella A. G., Sullivan S. E., Woo S. L. Correlation between polymorphic DNA haplotypes at phenylalanine hydroxylase locus and clinical phenotypes of phenylketonuria. J Pediatr. 1987 Jan;110(1):68–71. doi: 10.1016/s0022-3476(87)80290-1. [DOI] [PubMed] [Google Scholar]
  6. Lou H. C., Güttler F., Lykkelund C., Bruhn P., Niederwieser A. Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. Eur J Pediatr. 1985 May;144(1):17–20. doi: 10.1007/BF00491918. [DOI] [PubMed] [Google Scholar]
  7. Lykkelund C., Nielsen J. B., Lou H. C., Rasmussen V., Gerdes A. M., Christensen E., Güttler F. Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine. Eur J Pediatr. 1988 Dec;148(3):238–245. doi: 10.1007/BF00441411. [DOI] [PubMed] [Google Scholar]
  8. Malamud N. Neuropathology of phenylketonuria. J Neuropathol Exp Neurol. 1966 Apr;25(2):254–268. doi: 10.1097/00005072-196604000-00006. [DOI] [PubMed] [Google Scholar]
  9. McKean C. M. The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res. 1972 Dec 12;47(2):469–476. doi: 10.1016/0006-8993(72)90653-1. [DOI] [PubMed] [Google Scholar]
  10. NEAME K. D. Phenylalanine as inhibitor of transport of amino-acids in brain. Nature. 1961 Oct 14;192:173–174. doi: 10.1038/192173a0. [DOI] [PubMed] [Google Scholar]
  11. Pedersen H. E., Birket-Smith E. Neurological abnormalities in phenylketonuria. Acta Neurol Scand. 1974;50(5):589–598. doi: 10.1111/j.1600-0404.1974.tb02804.x. [DOI] [PubMed] [Google Scholar]
  12. TASHIAN R. E. Inhibition of brain glutamic acid decarboxylase by phenylalanine, valine, and leucine derivatives: a suggestion concerning the etiology of the neurological defect in phenylketonuria and branched-chain ketonuria. Metabolism. 1961 May;10:393–402. [PubMed] [Google Scholar]
  13. Thompson A. J., Smith I., Brenton D., Youl B. D., Rylance G., Davidson D. C., Kendall B., Lees A. J. Neurological deterioration in young adults with phenylketonuria. Lancet. 1990 Sep 8;336(8715):602–605. doi: 10.1016/0140-6736(90)93401-a. [DOI] [PubMed] [Google Scholar]
  14. Villasana D., Butler I. J., Williams J. C., Roongta S. M. Neurological deterioration in adult phenylketonuria. J Inherit Metab Dis. 1989;12(4):451–457. doi: 10.1007/BF01802042. [DOI] [PubMed] [Google Scholar]
  15. Williamson M. L., Koch R., Azen C., Chang C. Correlates of intelligence test results in treated phenylketonuric children. Pediatrics. 1981 Aug;68(2):161–167. [PubMed] [Google Scholar]
  16. Wood B. Neurological disturbance in a phenylketonic child after discontinuation of dietary treatment. Dev Med Child Neurol. 1976 Oct;18(5):657–660. doi: 10.1111/j.1469-8749.1976.tb04212.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES